MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

Search

Merck & Co Inc.

Open

BrancheGesundheitswesen

80.54 3.35

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

77.77

Max

79.93

Schlüsselkennzahlen

By Trading Economics

Einkommen

583M

3.7B

Verkäufe

-1B

16B

KGV

Branchendurchschnitt

11.55

57.333

EPS

1.72

Dividendenrendite

4.15

Gewinnspanne

23.963

Angestellte

73,000

EBITDA

1.3B

6.9B

Empfehlungen

By TipRanks

Empfehlungen

Buy

12-Monats-Prognose

+35.27% upside

Dividenden

By Dow Jones

Dividendenrendite

Branchendurchschnitt

4.15%

2.63%

Nächste Dividendenausschüttung

7. Juli 2025

Nächstes Ex-Dividendendatum

16. Juni 2025

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

-56B

196B

Vorheriger Eröffnungskurs

77.19

Vorheriger Schlusskurs

80.54

Technischer Score

By Trading Central

Vertrauen

Bullish Evidence

Merck & Co Inc. Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

9. Apr. 2025, 18:18 UTC

Wichtige Markttreiber

Pharma Shares Reverse Losses After Tariff Pause

9. Apr. 2025, 09:39 UTC

Wichtige Markttreiber

Pharma Stocks Tumble After Trump Threatens Tariffs on Medicines

4. Feb. 2025, 12:33 UTC

Ergebnisse

Merck 4Q Earnings Rise; 2025 Outlook Hits Shares -- Update

4. Feb. 2025, 11:57 UTC

Ergebnisse

Merck 4Q Sales Increase Results in Swing to Profit

24. Apr. 2025, 20:08 UTC

Ergebnisse

Gilead Sciences Earnings Were Solid. How the S&P 500's No. 1 Health Stock Did. -- Barrons.com

24. Apr. 2025, 16:05 UTC

Top News
Ergebnisse

Merck Cuts 2025 Outlook on Tariffs, Charges -- Update

24. Apr. 2025, 14:36 UTC

Market Talk
Ergebnisse

Merck's Challenges with Gardasil in China Continue -- Market Talk

24. Apr. 2025, 14:10 UTC

Market Talk
Ergebnisse

Merck's Mostly Steady Guidance Sees Current Tariffs Being Absorbed -- Market Talk

24. Apr. 2025, 11:35 UTC

Ergebnisse

Merck Lowers Earnings Guidance and Says Tariffs Will Hit Margins -- Barrons.com

24. Apr. 2025, 10:58 UTC

Top News
Ergebnisse

Merck 1Q Net Up, But 2025 Adj EPS View Cut on Tariffs, Charges

24. Apr. 2025, 10:55 UTC

Ergebnisse

Merck Stock Rises After Earnings Even as Keytruda Sales Miss Estimates. Here's Why. -- Barrons.com

24. Apr. 2025, 10:31 UTC

Ergebnisse

Merck: 2025 Outlook Absorbs Estimated $200 Million Additional Costs for Tariffs Implemented to Date >MRK

24. Apr. 2025, 10:30 UTC

Ergebnisse

Merck 1Q Keytruda Sales $7.21B >MRK

24. Apr. 2025, 10:30 UTC

Ergebnisse

Merck 1Q Pharmaceutical Sales $13.64B >MRK

24. Apr. 2025, 10:30 UTC

Ergebnisse

Merck 1Q Keytruda Sales Up 4% >MRK

24. Apr. 2025, 10:30 UTC

Ergebnisse

Merck 1Q Januvia/Janumet Sales Up 19% >MRK

24. Apr. 2025, 10:30 UTC

Ergebnisse

Merck 1Q Pharmaceutical Sales Down 3% >MRK

24. Apr. 2025, 10:30 UTC

Ergebnisse

Merck 1Q Gardasil/Gardasil 9 Sales $1.33B >MRK

24. Apr. 2025, 10:30 UTC

Ergebnisse

Merck 1Q Januvia/Janumet Sales $796M >MRK

24. Apr. 2025, 09:13 UTC

Heiße Aktien

Stocks to Watch Thursday: IBM, Tesla, Chipotle -- WSJ

24. März 2025, 05:00 UTC

Ergebnisse
Akquisitionen, Fusionen, Übernahmen

Chipotle and 4 More Buyback Stocks for a Down Market -- Barrons.com

5. März 2025, 19:42 UTC

Top News

New Version of Merck's Blockbuster Cancer Drug Threatened by Patent Battle -- Update

5. März 2025, 10:30 UTC

Top News

New Version of Merck's Blockbuster Cancer Drug Threatened by Patent Battle -- WSJ

5. Feb. 2025, 12:00 UTC

Top News

Merck Is Suffering From a Classic Pharma Problem -- Heard on the Street -- WSJ

4. Feb. 2025, 14:48 UTC

Ergebnisse

Merck Stock Plummets 10% As Gardasil Dynamics, 2025 Guidance Weigh On Shares -- IBD

4. Feb. 2025, 11:51 UTC

Ergebnisse

Merck's Soft Guidance Offsets Better-Than-Expected Fourth-Quarter Earnings -- MarketWatch

4. Feb. 2025, 11:50 UTC

Ergebnisse

Merck Stock Tumbles on Weak Guidance and Gardasil Sales Slump -- Barrons.com

4. Feb. 2025, 11:31 UTC

Ergebnisse

Merck 4Q Gardasil/Gardasil 9 Sales Down 17% >MRK

4. Feb. 2025, 11:31 UTC

Ergebnisse

Merck 4Q Gardasil/Gardasil 9 Sales $1.55B >MRK

4. Feb. 2025, 11:31 UTC

Ergebnisse

Merck 4Q Januvia/Janumet Sales Down 38% >MRK

Peer-Vergleich

Kursveränderung

Merck & Co Inc. Prognose

Kursziel

By TipRanks

35.27% Vorteil

12-Monats-Prognose

Durchschnitt 108 USD  35.27%

Hoch 138 USD

Tief 85 USD

Basierend auf 18 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Merck & Co Inc. – Dist angeboten haben.

Rating-Konsens

By TipRanks

Buy

18 ratings

11

Buy

7

Halten

0

Sell

Technischer Score

By Trading Central

77.85 / 80.02Unterstützung & Widerstand

Kurzfristig

Bullish Evidence

Mittelfristig

Strong Bearish Evidence

Langfristig

Bearish Evidence

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über Merck & Co Inc.

Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes under the Keytruda, Bridion, Adempas, Lagevrio, Belsomra, Simponi, and Januvia brands, as well as vaccine products consisting of preventive pediatric, adolescent, and adult vaccines under the Gardasil/Gardasil 9, ProQuad, M-M-R II, Varivax, RotaTeq, Live Oral, Vaxneuvance, Pneumovax 23, and Vaqta names. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. vIt has development and commercialization agreement for three of Daiichi Sankyo's deruxtecan ADC candidates, which include patritumab deruxtecan, ifinatamab deruxtecan, and raludotatug deruxtecan for the treatment of multiple solid tumors both as monotherapy and/or in combination with other treatments; and AstraZeneca PLC to co-development and co-commercialize AstraZeneca's Lynparza products for multiple cancer types, and Koselugo for multiple indications. It also has licensed to develop, manufacture and commercialize LM-299, a novel investigational PD-1/VEGF bispecific antibody from LaNova. The company also has a collaboration agreement with Eisai Co., Ltd., Bayer AG, and Ridgeback Biotherapeutics LP, as well Moderna, Inc. Merck & Co., Inc. was founded in 1891 and is headquartered in Rahway, New Jersey.